ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · IEX Real-Time Price · USD
10.22
0.00 (0.00%)
At close: Jul 19, 2024, 12:00 AM
10.08
-0.14 (-1.37%)
Pre-market: Jul 22, 2024, 8:20 AM EDT
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 100 employees as of December 31, 2023. The number of employees increased by 14 or 16.28% compared to the previous year.
Employees
100
Change (1Y)
14
Growth (1Y)
16.28%
Revenue / Employee
n/a
Profits / Employee
-$1,017,630
Market Cap
689.06M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 100 | 14 | 16.28% |
Dec 31, 2022 | 86 | 8 | 10.26% |
Dec 31, 2021 | 78 | 17 | 27.87% |
Dec 31, 2020 | 61 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Weave Communications | 844 |
Paragon 28 | 574 |
Phathom Pharmaceuticals | 452 |
SI-BONE | 344 |
Zymeworks | 278 |
UroGen Pharma | 201 |
Scholar Rock Holding | 150 |
Stoke Therapeutics | 110 |
ORIC News
- 5 days ago - ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer - GlobeNewsWire
- 16 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - GlobeNewsWire
- 2 months ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC - GlobeNewsWire
- 3 months ago - ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 4 months ago - ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates - GlobeNewsWire